Drawing for MICROPX MICRO PELLET DELIVERY SYSTEM

USPTO serial 79016999

MICROPX MICRO PELLET DELIVERY SYSTEM

Reviewed by CopyMark Law Group

Reg. 3344372Status 706Renewal
Filing date
Status date
Registration date
Nov 27, 2007
Examiner
ALI, STEPHANIE MARIE
Law office
GENERIC WEB UPDATE

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Need help with MICROPX MICRO PELLET DELIVERY SYSTEM?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*

Plus Government fees of $650

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Dionne Heard

Dionne Heard VOLPE & KOENIG PC30 S 17TH ST18th FloorPHILADELPHIA, PA 19103

Goods and services

ClassDescriptionStatusFirst use
005[ Pharmaceutical preparations for the treatment, including prophylactic treatment, of disorders of the Central Nervous System (CNS), namely, psychopharmacologic drugs, soporifics, analeptics, analgetics, local anesthetics, general anesthetics, myorelaxants, anti-epileptics, anticonvulsants, antiparkinsonian agents, anti-emetics, sympathomimetics and/or parasympathomimetics; disorders of the hormonal system, namely, hypothalamic hormones, anterior pituitary hormones, therapeutics for thyroid disorders, therapeutics for diabetes, therapeutics for disorders of the adrenal cortex, sexual hormones and/or antihistaminics; disorders of the cardiovascular system, namely, drugs for the treatment of blood diseases, insufficiency of the heart, diseases of the vascular system, other heart diseases and/or hypertonia; disorders of the respiratory system, namely, anti-asthmatics and/or antitussives; disorders of the gastro-intestinal tract, namely, antacids, prokinetics, ulcus drugs, drugs for the treatment of Colitis ulcerosa and Crohn's disease, drugs for the treatment of obstipation, drugs for the treatment of diarrhoea, choleretics or cholagogues, other hepatotherapeutics and/or contrast media; renal and urinary tract disorders, namely, diuretics or antidiuretics; dermal disorders, namely, dermatotherapeutics; micronutrients, vitamins and/or trace elements; infectious diseases, namely, disinfectants and/or anti-infectives; cancer diseases, namely, antimetabolites, antibiotics with cytostatic effect, other cytostatics, and/or hormones and hormone antagonists; disorders of the immune system, namely, immunosuppressives or other immunomodulators ]SECTION 71 - CANCELLED
040[ Rental of devices and machines to third parties, namely, fluid bed machines and spray dry granulators for use in granulating, pelletizing, drying, coating, agglomerating medicines and medicaments for solid and oral dosage forms, except those used in the manufacture of pyridoxine or those used in the treatment of pyridoxine ]SECTION 71 - CANCELLED
042Scientific research and development of technologies for the manufacture of pharmaceuticalsACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 26, 2025RNWLINTERNATIONAL REGISTRATION RENEWED
Oct 11, 2019NREPNEW REPRESENTATIVE AT IB RECEIVED
Mar 16, 2018INNAINVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Mar 7, 2018INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Jul 7, 2017NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Jul 7, 201771AGREGISTERED-SEC.71 ACCEPTED
Jul 5, 2017ES71TEAS SECTION 71 RECEIVED
Nov 27, 2016REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Jun 19, 2015INNPPARTIAL INVALIDATION PROCESSED BY THE IB
Jun 18, 2015RNWLINTERNATIONAL REGISTRATION RENEWED
Feb 6, 2015INPSPARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Feb 6, 2015INPCINVALIDATION PROCESSED
Aug 12, 2014INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Dec 11, 2013NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Dec 11, 2013C75PREGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
Dec 11, 2013APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 27, 2013715FREGISTERED - SEC. 71 & SEC. 15 FILED
Nov 27, 2013ES75TEAS SECTION 71 & 15 RECEIVED
Jun 12, 2009FINOFINAL DECISION TRANSACTION PROCESSED BY IB
Mar 12, 2008FICSFINAL DISPOSITION NOTICE SENT TO IB
Mar 12, 2008FIMPFINAL DISPOSITION PROCESSED
Feb 27, 2008FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 27, 2007R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 11, 2007PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 22, 2007NPUBNOTICE OF PUBLICATION
Aug 6, 2007PREVLAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 4, 2007CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
May 18, 2007TEMETEAS/EMAIL CORRESPONDENCE ENTERED
May 18, 2007CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
May 18, 2007ALIEASSIGNED TO LIE
May 10, 2007OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 27, 2007TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 26, 2007OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 26, 2007OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Oct 30, 2006CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Oct 27, 2006CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 20, 2006TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Jul 7, 2006CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 7, 2006TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 5, 2006ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 5, 2006REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 27, 2006RFNTREFUSAL PROCESSED BY IB
Jan 9, 2006RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 22, 2005RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 21, 2005CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 21, 2005DOCKASSIGNED TO EXAMINER
Nov 30, 2005NWAPNEW APPLICATION ENTERED
Nov 28, 2005REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Frequently asked questions

Related guidance